Pancare playing an increasingly important role advocating for awareness of upper GI cancer

Pancare is playing an increasingly important role in advocating for greater awareness of pancreatic and upper GI cancers across Australia. We are aiming to help deliver better outcomes and improved quality of life through research, service and support for the thousands of people affected by these cancers every year.

We are fully invested in the development of the National Pancreatic Cancer Roadmap, with Pancare Medical Advisory Committee Chair, AProf Mehrdad Nikfarjam, and CEO Doug Hawkins playing key roles in the multidisciplinary Roadmap Steering Group. The Pancare team participated in the public consultation, submitting a 15-page report in November 2020 on behalf of the Pancare community and covered all aspects of pancreatic cancer care from care pathways, service availability, clinical management, research, new treatments, finances, multicultural support through to bereavement, caring for the carer, emotional support and everything in between.  

Led by Cancer Australia, the roadmap is set to be delivered in December 2021.

Open consultations include:

• Federation of Ethnic Communities’ Councils if Australia (FECCA) consultation for pancreatic cancer patients and carers from culturally and linguistically diverse backgrounds as part of the National Pancreatic Cancer Roadmap development. Pancreatic cancer – FECCA
• Stakeholder engagement for National Pancreatic Cancer Roadmap development for health professionals, patients and carers with follow-up interviews and group discussions.
• Public consultation for Pharmaceutical Benefits Scheme listing of new medication for oesophageal and oesophagogastric (junctional) cancer called nivolumab (Opdivo). (Closes Wednesday May 26, 2021)

Your stories, experiences and opinions matter, and they are powerful tools that can effect change on a national – even international – level.  

Please contact the PanSupport team on [email protected] or call 1300 881 698 to share your experience with us.